Suppr超能文献

健康中年人群经 HeartScore 风险分层和冠状动脉钙化扫描后 6 个月的治疗变化。

Changes in medical treatment six months after risk stratification with HeartScore and coronary artery calcification scanning of healthy middle-aged subjects.

机构信息

Department of Cardiology, Odense University Hospital, Odense, Denmark.

出版信息

Eur J Prev Cardiol. 2012 Dec;19(6):1496-502. doi: 10.1177/1741826711428063. Epub 2011 Oct 21.

Abstract

OBJECTIVES

The aim was to examine and compare the impact of HeartScore and coronary artery calcification (CAC) score on subsequent changes in the use of medication.

METHODS

A total of 1156 healthy men and women, aged 50 or 60, had a baseline medical examination and a coronary artery CT-scan as a part of a screening programme. Using the European HeartScore, the total 10-year cardiovascular mortality risk was estimated (≥5% risk was considered as high). Risk factors and CAC scores were reported to both the patients and their general practitioner. Six months after the screening, follow-up questionnaires addressing current medication were mailed to the participants.

RESULTS

A completed questionnaire was returned by 1075 (93%) subjects. At follow up, the overall use of prophylactic medication was significantly increased. Of those with CAC (n = 462) or high HeartScore (n = 233), 21 and 19%, respectively, received lipid-lowering treatment, while 25 and 32%, respectively, received antihypertensive treatment. In multivariate logistic regression analyses, the presence of CAC was associated with an increased use of lipid-lowering treatment (OR 2.2; 95% CI 1.2-4.0), while the presence of a high HeartScore was associated with an increased use of lipid-lowering (OR 2.9; 95% CI 1.6-5.5) and antihypertensive medication (OR 3.4; 95% CI 1.9-6.0).

CONCLUSION

Knowledge of present cardiovascular risk factors like high HeartScore and/or CAC leads to beneficial changes in medication. However, at follow up only a minority of high-risk subjects did received prophylactic treatment. CAC score was not superior to HeartScore regarding these motivational outcomes.

摘要

目的

旨在探讨和比较 HeartScore 和冠状动脉钙化(CAC)评分对随后药物使用变化的影响。

方法

共有 1156 名年龄为 50 或 60 岁的健康男性和女性参加了一项筛查计划,接受了基线体检和冠状动脉 CT 扫描。使用欧洲 HeartScore 评估了总 10 年心血管死亡率风险(≥5%的风险被认为是高风险)。危险因素和 CAC 评分均报告给患者及其全科医生。在筛查后 6 个月,向参与者邮寄了一份关于当前用药情况的随访问卷。

结果

1075 名(93%)参与者完成了问卷调查。随访时,预防性药物的总体使用量显著增加。在 CAC(n=462)或高 HeartScore(n=233)患者中,分别有 21%和 19%接受了降脂治疗,而分别有 25%和 32%接受了降压治疗。多变量逻辑回归分析显示,CAC 的存在与降脂治疗的使用增加相关(OR 2.2;95% CI 1.2-4.0),而高 HeartScore 的存在与降脂治疗(OR 2.9;95% CI 1.6-5.5)和降压药物(OR 3.4;95% CI 1.9-6.0)的使用增加相关。

结论

了解高 HeartScore 和/或 CAC 等当前心血管危险因素会导致药物治疗的有益变化。然而,在随访时,只有少数高危患者接受了预防性治疗。在这些激励结果方面,CAC 评分并不优于 HeartScore。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验